Abbott LaboratoriesABTNYSE
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank54
5Y CAGR-32.2%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-32.2%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 9.43% |
| Q3 2025 | 0.24% |
| Q2 2025 | 21.56% |
| Q1 2025 | -15.18% |
| Q4 2024 | 9.46% |
| Q3 2024 | 7.83% |
| Q2 2024 | 21.73% |
| Q1 2024 | -25.70% |
| Q4 2023 | 11.08% |
| Q3 2023 | 11.05% |
| Q2 2023 | 7.93% |
| Q1 2023 | -2.85% |
| Q4 2022 | -15.38% |
| Q3 2022 | -27.00% |
| Q2 2022 | -19.13% |
| Q1 2022 | 17.90% |
| Q4 2021 | -6.67% |
| Q3 2021 | 31.23% |
| Q2 2021 | -6.33% |
| Q1 2021 | -11.64% |
| Q4 2020 | 65.80% |
| Q3 2020 | 126.79% |
| Q2 2020 | -17.59% |
| Q1 2020 | -44.56% |
| Q4 2019 | 16.89% |
| Q3 2019 | 1.01% |
| Q2 2019 | 56.79% |
| Q1 2019 | -35.46% |
| Q4 2018 | 12.00% |
| Q3 2018 | 10.88% |
| Q2 2018 | 41.13% |
| Q1 2018 | -8.71% |
| Q4 2017 | -18.78% |
| Q3 2017 | 133.25% |
| Q2 2017 | 687.88% |
| Q1 2017 | -106.77% |
| Q4 2016 | 6.21% |
| Q3 2016 | 12.50% |
| Q2 2016 | 55.73% |
| Q1 2016 | -35.71% |